Oryzon Genomics, S.A.
Records under this name other than the patents Oryzon Genomics, S.A. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 24 patents it holds.
Showing 1 to 10 of 10 · Back to Oryzon Genomics, S.A.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,790,196 | Lysine demethylase inhibitors for diseases and disorders associated with Flaviviridae Lapsed on the fee record Ended Oct 17, 2025 · From the USPTO record | Lapsed on the fee record | Ended Oct 17, 2025 | From the USPTO record |
| US 9,676,701 | Cyclopropylamine derivatives useful as LSD1 inhibitors Lapsed on the fee record Ended Jun 13, 2025 · From the USPTO record | Lapsed on the fee record | Ended Jun 13, 2025 | From the USPTO record |
| US 9,616,058 | Potent selective LSD1 inhibitors and dual LSD1/MAO-B inhibitors for antiviral use Lapsed on the fee record Ended Apr 11, 2025 · From the USPTO record | Lapsed on the fee record | Ended Apr 11, 2025 | From the USPTO record |
| US 9,186,337 | Lysine demethylase inhibitors for diseases and disorders associated with Hepadnaviridae Lapsed on the fee record Ended Nov 17, 2023 · From the USPTO record | Lapsed on the fee record | Ended Nov 17, 2023 | From the USPTO record |
| US 9,061,966 | Cyclopropylamine inhibitors of oxidases Lapsed on the fee record Ended Jun 23, 2023 · From the USPTO record | Lapsed on the fee record | Ended Jun 23, 2023 | From the USPTO record |
| US 9,006,449 | Cyclopropylamine derivatives useful as LSD1 inhibitors Lapsed on the fee record Ended Apr 14, 2023 · From the USPTO record | Lapsed on the fee record | Ended Apr 14, 2023 | From the USPTO record |
| US 10,214,477 | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors Lapsed on the fee record Ended Feb 26, 2023 · From the USPTO record | Lapsed on the fee record | Ended Feb 26, 2023 | From the USPTO record |
| US 8,946,296 | Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use Lapsed on the fee record Ended Feb 3, 2023 · From the USPTO record | Lapsed on the fee record | Ended Feb 3, 2023 | From the USPTO record |
| US 8,859,555 | Lysine Specific Demethylase-1 inhibitors and their use Lapsed on the fee record Ended Oct 14, 2022 · From the USPTO record | Lapsed on the fee record | Ended Oct 14, 2022 | From the USPTO record |
| US 7,745,127 | Molecular diagnostic method for dementia with lewy bodies Lapsed on the fee record Ended Jun 29, 2014 · From the USPTO record | Lapsed on the fee record | Ended Jun 29, 2014 | From the USPTO record |